Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Saving Babies Through Birth Defects Prevention and Research

A pregnant woman holding her belly
Saving Babies

CDC’s NCBDDD is working toward a day when all babies are born with the best health possible.

Birth defects and infant disorders, such as fetal alcohol spectrum disorders, are common, costly, and critical. Our unique state-based birth defects tracking, public health research, and world-renowned expertise provide a wealth of information used to

  • Identify causes of birth defects and infant disorders;
  • Find opportunities to prevent them; and
  • Improve the health of babies born with these conditions.

Together with states, academic centers, healthcare providers, and other partners, we are working toward a day when all babies are born with the best health possible and every child thrives.

Accomplishments

  • Contributed to what is known about Zika virus infection during pregnancy. Information collected from the U.S. Zika Pregnancy and Infant Registry was used to advance public health action to protect mothers and babies from Zika virus infection. In addition, data from this innovative monitoring system led to
    • Better understanding of the impact of Zika virus infection during pregnancy;
    • Updated clinical care recommendations;
    • Planning for medical and social services for families affected by Zika virus; and
    • Improved prevention of Zika virus infection during pregnancy.
  • Advanced the efforts examining the effectiveness of mandated screening for critical congenital heart defects (CCHDs) and the long-term outcomes and healthcare needs for children born with heart defects. Mandated CCHD screening nationwide was estimated to potentially save the lives of 120 babies each year. NCBDDD estimated that 1 in 77 U.S. children were living with heart conditions in 2016 and that these children were more likely to have special healthcare needs, such as medication needs or physical or speech therapy. This research quantifies the impact of mandated CCHD screening, identifies the needs of those living with heart defects, and helps inform resource planning for this growing population.
  • Expanded research and delivered reliable information about the use of certain medications, such as antibiotics and medications for attention-deficit/hyperactivity disorder, among pregnant women and women of reproductive age. These results from studies by NCBDDD researchers, using data from the National Birth Defects Prevention Study, provide a basis for further studies on medications identified as having a potential risk for birth defects. NCBDDD also provided new information on medication use during pregnancy through the Treating for Two website.
  • Focused new fetal alcohol spectrum disorder (FASD) activities on
    • Implementing alcohol screening and brief intervention in health systems that provide women’s health services;
    • Expanding capacity of national professional organizations in the prevention, identification, and management of FASDs; and
    • Promoting resources for FASD awareness and prevention.
  • Collaborated across CDC to evaluate a possible link between neural tube defects among infants born to women living with human immunodeficiency virus (HIV) and the use of the medication, dolutegravir, in early pregnancy. This comprehensive evaluation considered all risks and benefits to both mother and baby for the use of dolutegravir in early pregnancy.

Looking to the Future

NCBDDD will continue its work to protect women and babies through birth defects tracking and public health research. These activities provide knowledge about the factors that might increase or decrease the risk of having a baby with a birth defect or infant disorder. NCBDDD’s work on Zika virus is a reminder of the medical vulnerability of mothers and babies to emerging infections and other health threats, such as the opioid crisis and natural disasters. With new funding received for fiscal year 2019 for Surveillance of Emerging Threats to Mothers and Babies, NCBDDD will continue to leverage the innovative tracking and monitoring system developed to combat Zika virus, work to understand the full impact of Zika virus on infants and children, and pilot this system to capture data on other emerging threats that may affect mothers and babies. With new funding received for fiscal year 2019 for neonatal abstinence syndrome, NCBDDD will expand work with states and partners to build upon birth defects surveillance systems and explore more accurate ways of estimating the number of infants who have neonatal abstinence syndrome and the health needs for these children.

Notable Scientific Publications

Abouk R, Grosse SD, Ailes EC, Oster ME. Association of US state implementation of newborn screening policies for critical congenital heart disease with early infant cardiac deaths. JAMA. 2017;318(21):2111-2118.

Anderson KN, Ailes EC, Danielson M, et al. Attention-deficit/hyperactivity disorder medication prescription claims among privately insured women aged 15–44 years — United States, 2003–2015. MMWR Morb Mortal Wkly Rep. 2018;67(2):66–70.

Anderson KN, Dutton AC, Broussard CS, et al. ADHD medication use during pregnancy and risk for selected birth defects: National Birth Defects Prevention Study, 1998-2011. J Atten Disord. 2018 Mar. [Epub ahead of print]

Chen M, Riehle-Colarusso T, Yeung LF, Smith C, Farr SL. Children with Heart Conditions and Their Special Health Care Needs — United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67:1045–1049.

Crider KS, Qi YP, Devine O, Tinker SC, Berry RJ. Modeling the impact of folic acid fortification and supplementation on red blood cell folate concentrations and predicted neural tube defect risk in the United States: have we reached optimal prevention? Am J Clin Nutr. 2018;107(6):1027-1034.

Delaney A, Mai C, Smoots A, et al. Population-Based Surveillance of Birth Defects Potentially Related to Zika Virus Infection — 15 States and U.S. Territories, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(3):91-96.

McClung N, Glidewell J, Farr SL. Financial burdens and mental health needs in families of children with congenital heart disease. Congenit Heart Dis. 2018;13(4):554-562.

Polen KD, Gilboa SM, Hills S, et al. Update: Interim guidance for preconception counseling and prevention of sexual transmission of Zika virus for men with possible Zika virus exposure — United States, August 2018. MMWR Morb Mortal Wkly Rep. 2018;67(31):868-871.

Raut JR, Simeone RM, Tinker SC, et al. Proportion of orofacial clefts attributable to recognized risk factors. Cleft Palate Craniofac J. 2018 Jan. [Epub ahead of print]

Rice ME, Galang RR, Roth NM, et al. Vital Signs: Zika-associated birth defects and neurodevelopmental abnormalities possibly associated with congenital Zika virus infection — U.S. territories and freely associated states, 2018. MMWR Morb Mortal Wkly Rep. 2018;67(31):858-867.

Video

Suspect Congenital Zika? What to Do Next

Watch Dr. Cynthia Moore, a medical officer at CDC, talk about the importance of follow-up for infants and children with possible congenital Zika virus infection and CDC’s recommendations for evaluating these infants.

Spotlight on: American Academy of Pediatrics

Zika Response

Since 2016, the American Academy of Pediatrics (AAP) has worked hand-in-hand with the Centers for Disease Control and Prevention (CDC) National Center on Birth Defects and Developmental Disabilities (NCBDDD) to ensure that infants impacted by Zika virus were identified, reported, and provided immediate and long-term treatment and care. This included input on updated clinical guidance, articles, and resources for clinicians, such as psychosocial support materials and an AAP Periodic Survey of Fellows to learn about pediatricians’ experiences with, and attitudes toward, infectious disease and disaster preparedness, with a focus on Zika virus. The AAP also partnered with the American College of Obstetricians and Gynecologists (ACOG) to conduct a national survey of its membership and focus groups, and evaluation of AAP/ACOG support to Zika contractual field assignees within local health departments. The AAP continues to express that

  • Clinicians remain vigilant in preventing Zika during pregnancy;
  • Healthcare providers provide consistent and clear presentation of information from provider-to-provider and from provider-to-patient; and
  • Developing babies with suspected or possible congenital (present at birth) Zika virus infection (gets in your body) need continued monitoring (watching) within a medical home.

The AAP believes this work and these collaborations are important to ensure the optimal health and development of infants with congenital Zika virus exposure.

Fetal Alcohol Spectrum Disorders

Prenatal exposure to alcohol is the leading preventable cause of birth defects, intellectual disabilities, and neurodevelopmental disorders. The non diagnostic umbrella term fetal alcohol spectrum disorders (FASDs) is used to characterize the full range of diagnoses resulting from prenatal alcohol exposure. Research and other published data continue to document missed and underdiagnosed FASDs. Early identification of a child at risk for an FASD is facilitated by screening for prenatal alcohol exposure. Information to support pediatricians is available at www.aap.org/pae.

Through grant funding from NCBDDD, AAP has worked with the National Organization on Fetal Alcohol Syndrome and two university-based Practice and Implementation Centers at the University of California-San Diego and the University of Wisconsin-Madison. Through these partnerships, the centers developed multiple educational resources to ensure pediatric clinicians have the capacity to identify and manage the care for children with FASDs. These are available at www.aap.org/fasd.

TOP